Home : Latest News : Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA Phase 2 Data Anticipated in Second Quarter of 2012
Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA Phase 2 Data Anticipated in Second Quarter of 2012